Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics Inc. (NASDAQ: CADL) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage